New Appointment Marks Critical Step Forward as RLS Continues to Build a World-Class Leadership Team and Expand into New Areas in Nuclear Medicine

随着RLS继续建立世界一流的领导团队并扩展到核医学的新领域，新的任命标志着向前迈出的关键一步

LAKE ZURICH, Ill., Sept. 5, 2023 /PRNewswire/ -- Today, RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear pharmacy network in the US, announced the appointment of industry veteran Matt Molchan as Senior Vice President of Business Development. With over two decades of experience in nuclear medicine and healthcare, Molchan will play a key role in driving new business growth as RLS continues to scale and expand into new areas, ranging from clinical trials and CDMO work to PET and patient dose distribution..

2023年9月5日，伊利诺伊州苏黎世湖/PRNewswire/-今天，RLS（美国），Inc。（放射性同位素生命科学），美国第三大核药房网络，宣布任命行业退伍军人Matt Molchan担任业务发展高级副总裁。凭借二十多年的核医学和医疗保健经验，随着RLS不断扩大并扩展到从临床试验和CDMO工作到PET和患者剂量分布等新领域，Molchan将在推动新业务增长方面发挥关键作用。。

'RLS continues to build a world-class leadership team to create an unbroken chain in patient care, from clinical trial to commercial supply,' said Stephen Belcher, CEO of RLS. 'With a proven track record in nuclear medicine, Matt will help to unlock the next phase of business growth for RLS. Adding Matt to the team is another critical step in the right direction as we continue to expand into new areas and establish strategic partnerships with other industry leaders, positioning RLS for long-term and sustainable growth.'.

RLS首席执行官Stephen Belcher说：“RLS继续建立一个世界级的领导团队，在从临床试验到商业供应的患者护理中创建一个完整的链条。”凭借核医学领域的良好记录，Matt将有助于解开RLS业务增长的下一阶段。随着我们继续扩展到新领域并与其他行业领导者建立战略伙伴关系，将RL定位于长期可持续增长，将Matt添加到团队中是朝着正确方向迈出的另一个关键步骤。

As Senior Vice President of Business Development, Molchan will lead business development strategy and execution for RLS, identifying new opportunities as the radiopharmacy network expands. His role will include setting national, regional and local business development strategy across the RLS network, which includes 31 radiopharmacies across 18 states in top markets nationwide.

作为业务发展的高级副总裁，Molchan将领导RLS的业务发展战略和执行，随着放射性药物网络的扩展，确定新的机会。他的职责将包括在RLS网络中制定国家，区域和地方业务发展战略，其中包括全国顶级市场18个州的31家放射性药房。

In addition, Molchan will be responsible for building and maintaining strategic partnerships between RLS and other industry-leading radiopharmacy firms..

此外，Molchan将负责建立和维护RLS与其他行业领先的放射性制药公司之间的战略合作伙伴关系。。

Molchan brings over 20 years of experience in healthcare leadership, with a focus on nuclear medicine and ultrasound imaging. Prior to joining RLS, he served as President and CEO of Digirad, a leading medical device manufacturer and healthcare service provider. Previously, he served in executive-level roles at Digirad Imaging Solutions and Ultrascan, a mobile ultrasound service business.

Molchan拥有20多年的医疗保健领导经验，专注于核医学和超声成像。在加入RLS之前，他曾担任领先的医疗设备制造商和医疗服务提供商Digirad的总裁兼首席执行官。此前，他曾在Digirad Imaging Solutions和Ultrascan（一家移动超声服务业务）担任执行级职位。

Molchan holds a B.S. in Economics from the United States Air Force Academy and an MBA from the University of Southern California..

Molchan拥有美国空军学院的经济学士学位和南加州大学的MBA学位。。

About RLS

关于RLS

RLS (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications.

RLS（放射性同位素生命科学）是美国第三大核医学制药网络，在18个州拥有并运营31家放射性药房，提供广泛的分子成像产品组合。我们努力通过在符合ISO 1644-1规范的洁净室中分配100%的可注射单位剂量产品来提供行业中最高质量的放射性药物。

In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers. For more information, please visit www.rls.bio..

为了支持我们对质量的承诺，我们为1500多名客户提供量身定制的解决方案和卓越的服务。欲了解更多信息，请访问www.rls.bio。。

For more information, please contact:

欲了解更多信息，请联系：

RLS (USA), Inc.Trey BanksonChief Operating Officer[email protected]

RLS（美国），Inc。Trey Bankson首席运营官[电子邮件保护]

SOURCE RLS (USA) Inc.

源RLS（美国）公司。